Effects of Subanesthetic Isoflurane/Sevoflurane in 60% Oxygen on Clinical In-vitro Experimental Sepsis
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02185118|
Recruitment Status : Unknown
Verified July 2014 by Lichao Hou, Fourth Military Medical University.
Recruitment status was: Recruiting
First Posted : July 9, 2014
Last Update Posted : July 9, 2014
Sepsis is a major cause of death in intensive care units. Despite the investigators improved understanding, which has reduced the risk of dying with sepsis, the number of people who die each year continues to increase due to an overall increase in the number of cases.In our previous study, the investigators have showed that 100% oxygen or 0.5 minimum alveolar concentration (MAC) isoflurane/sevoflurane in 60% oxygen protect mouse macrophage cell line against in-vitro sepsis induced by lipopolysaccharide (LPS).
In this study, the investigator hypothesized that treatment of 100% oxygen or 0.5 MAC isoflurane/sevoflurane in 60% oxygen protected against clinical in-vitro models of sepsis induced by LPS or plasma from septic patients.
|Condition or disease||Intervention/treatment||Phase|
|Sepsis||Drug: oxygen Drug: Sevoflurane Drug: Isoflurane||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||50 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||In-vitro Experimental Study About Effects of Subanesthetic Isoflurane/Sevoflurane in 60% Oxygen on Clinical In-vitro Sepsis|
|Study Start Date :||June 2014|
|Estimated Primary Completion Date :||June 2018|
|Estimated Study Completion Date :||July 2018|
Experimental: oxygen plus isoflurane/sevoflurane
All human peripheral blood mononuclear cells (PBMCs) were from patients with non sepsis/non SIRS/non infection.
The above cells were treated with oxygen or oxygen plus isoflurane/sevoflurane after stimulation of lipopolysaccharide/plasma from septic patients.
Other Name: 100% oxygen
Other Name: subanesthetic sevoflurane in 60% oxygen
Other Name: subanesthetic isoflurane in 60% oxygen
- Subcellular location of Nuclear Factor-KAPPA B p65 subunit [ Time Frame: within 10 hours after the intervention ]
- tumor necrosis factor-alpha [ Time Frame: within 10 hours after the intervention ]
- interleukin- 1 beta [ Time Frame: within 10 hours after the intervention ]
- interleukin 6 [ Time Frame: within 10 hours after the intervention ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02185118
|Contact: Lichao Hou, M.D., Ph.D.||email@example.com|
|Department of Anesthesiology, Xijing Hospital, Fourth Military Medical University,||Recruiting|
|Xi'an, Shaanxi, China, 710032|
|Contact: lichao Hou firstname.lastname@example.org|
|Principal Investigator:||Lichao Hou, M.D., Ph.D.||Fourth Military Medical University|